Arrowhead Research | ARWR - 销售收入



金融业
股票价格
USD
资产
USD 2.11B
现金及等价物
USD 19.69M
流动资产
USD 1.67B
流动负债
USD 283.35M
债务
USD 983.69M
EBIT
USD -154.34M
EBITDA
USD -147.68M
员工
711
EPS每股收益
USD -1.36
股本和储备
USD 465.53M
销售毛利
USD 75.25M
债务利息支出
USD 24.56M
利息收入
USD 16.94M
贷款资金
USD 824.07M
市值
USD 10.5B
净收入
USD -194.28M
营业费用
USD 245.35M
营业利润
USD -170.09M
普通股股本
USD 141.14M
PE价格收益
39.19
税前利润
USD -178.91M
销售收入
USD 75.23M
销售和管理费用
USD 46.63M
股票
USD -173.09M
贸易债权人
USD 27.78M
应收帐款人
USD 8.56M


销售 更改 日
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 75.23M 1.49M 2026-06
Heron Therapeutics USD 40.59M 2.38M 2025-12
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Ligand Pharmaceuticals USD 83.7M 31.98M 2026-06
Merck USD 16.6B 310M 2026-06
Moderna USD 100M 289M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Novartis USD 14.41B 1.3B 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
TG Therapeutics USD 240.34M 45.54M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06
Xencor USD 51.22M 46.71M 2026-06